



Press Release

inscreenex and YUMAB partner to develop next-generation Mammalian Display platform for antibody discovery

04 February 2025

- Collaboration between **inscreenex** and YUMAB to develop Mammalian Display platform for antibody discovery.
- Funded under the Lower Saxony Innovation Funding Program for Research and Development in Companies, the project is backed by a total budget of €1.6Mio.
- The innovative platform will allow the efficient screening of large antibody libraries directly in mammalian cells therefore speeding up therapeutic antibody development.

inscreenex GmbH, a premier supplier of highly customized and functional cell lines for drug discovery, and YUMAB GmbH, a German biotechnology company specializing in contract research for therapeutic antibodies, today announced a collaboration in the publicly funded "Mammalian Display" project, a groundbreaking initiative set to redefine antibody discovery. The project, funded under the Lower Saxony Innovation Funding Program, is backed by a total budget of €1.6 million, with €1 million in grant funding, and will run until 2027.

Revolutionizing Antibody Discovery with Mammalian Display

Traditional antibody development pipelines often suffer from inefficiencies, requiring late-stage manufacturability testing that can lead to project failures. The Mammalian Display platform overcomes these challenges by screening antibody candidates early and directly within mammalian production cells, eliminating unnecessary intermediate steps. The expected 10-fold increase in efficiency will not only accelerate therapeutic antibody development but will also ensure that selected candidates are suitable for manufacturing from the outset.

Highly Efficient Landing Pad Technology

At the core of this collaboration is **inscreenex's** Landing Pad Technology, a site-specific, single-copy gene integration system that provides a level of efficiency beyond conventional site-specific integration technologies. This higher efficiency enables the use of antibody libraries for Mammalian Display exceeding 10 million unique candidates while maintaining reasonable cost and scalability.

"Through innovative technologies like our Landing Pad Technology, we can significantly increase efficiency and precision in antibody development." said Dr. Roland Schucht, CEO of **inscreenex** GmbH. "Together, we are setting new standards in the research and production of therapeutic antibodies."

Dr. Thomas Schirrmann, CEO of YUMAB, is pleased about the funding of the project: "This funding project provides both companies with the opportunity to combine the strengths of their technology platforms, thereby accelerating the development of cutting-edge biotherapeutics, including bispecific antibody drugs, in a way that has never been possible before or making it possible at all." the scientific community with high-quality cell lines and efficient delivery services, ultimately accelerating the development of new therapies."



About inscreenex GmbH

inscreenex is a biotechnology company specializing in the generation of highly customized and functional cell lines for drug discovery and development. Utilizing advanced technologies, inscreenex provides researchers with tailored cell line solutions that enable more accurate and efficient drug screening processes. For more information, visit inscreenex.com.

About YUMAB GmbH

YUMAB GmbH was founded in 2012 by scientists from the Technical University of Braunschweig. The research company develops therapeutic antibodies from target identification to optimized lead candidates for biotechnology and pharmaceutical companies worldwide. With its unique technology platforms, YUMAB supports the value creation of its customers by delivering a wide range of new human and humanized antibody biologics quickly and with a high success rate. Our team embraces innovation and supports collaborations with partners from both science and industry to meet the future needs of biotech and pharmaceutical customers globally. For more information, visit yumab.com.

Contact

inscreenex GmbH
Inhoffenstr. 7
38124 Braunschweig
Germany

Dr. Tom Pietrobelli (BD&Licensing)
info@inscreenex.com



Kofinanziert von der
Europäischen Union

